Quest Diagnostics Inc. insider trading
DGXfinancial statementsForm 4 filings on EDGAR272 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Quest Diagnostics Inc. bought $0 of stock in the open market, and 3 sold $8M. Officers and directors accounted for $0 of purchases and $8M of sales. The last reported transaction was an open-market sale by Pfeiffer Gary M on October 26, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 28, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $8MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
272 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | Pfeiffer Gary M | Director | open-market sale10b5-1 | 1,203 | $243.00 | $292K | 29,802 | Oct 28, 2026 |
| Oct 21, 2026 | Carter Robert B | Director | small acquisition | 10 | $235.93 | $2K | 3,874 | Oct 23, 2026 |
| Oct 21, 2026 | Samad Sam | Executive Vice President & CFO | award | 90 | $235.94 | $21K | 33,568 | Oct 23, 2026 |
| Oct 21, 2026 | Gregg Vicky B | Director | award | 63 | $235.94 | $15K | 18,449 | Oct 23, 2026 |
| Oct 21, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | small acquisition | 33 | $235.94 | $8K | 13,619 | Oct 23, 2026 |
| Oct 21, 2026 | Lassiter Wright III | Director | small acquisition | 6 | $235.96 | $1K | 10,329 | Oct 23, 2026 |
| Oct 21, 2026 | Plewman Patrick | SVP for Diagnostic Services | small acquisition | 41 | $235.94 | $10K | 15,334 | Oct 23, 2026 |
| Oct 21, 2026 | Main Timothy L | Director | small acquisition | 18 | $235.94 | $4K | 22,478 | Oct 23, 2026 |
| Oct 21, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | small acquisition | 25 | $235.94 | $6K | 10,360 | Oct 23, 2026 |
| Sep 1, 2026 | Davis J. E. | CEO and President, Director | open-market sale10b5-1 | 10,000 | $242.72 | $2M | 122,423 | Sep 3, 2026 |
| Aug 28, 2026 | Prevoznik Michael E | SVP & General Counsel | option exercise | 22,677 | $112.17 | $3M | 60,234 | Aug 31, 2026 |
| Aug 28, 2026 | Prevoznik Michael E | SVP & General Counsel | open-market sale10b5-1 | 16,010 | $242.88 | $4M | 44,224 | Aug 31, 2026 |
| Aug 28, 2026 | Prevoznik Michael E | SVP & General Counsel | open-market sale10b5-1 | 6,237 | $243.63 | $2M | 37,987 | Aug 31, 2026 |
| Aug 28, 2026 | Prevoznik Michael E | SVP & General Counsel | open-market sale10b5-1 | 430 | $244.51 | $105K | 37,557 | Aug 31, 2026 |
| Aug 28, 2026 | Prevoznik Michael E | SVP & General Counsel | gift | 1,000 | $0.00 | — | 36,557 | Aug 31, 2026 |
| Jul 28, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | open-market sale10b5-1 | 1,600 | $235.18 | $376K | 10,335 | Jul 29, 2026 |
| Jul 22, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | small acquisition | 37 | $206.81 | $8K | 13,557 | Jul 27, 2026 |
| Jul 22, 2026 | Carter Robert B | Director | small acquisition | 11 | $206.80 | $2K | 3,864 | Jul 27, 2026 |
| Jul 22, 2026 | Gregg Vicky B | Director | award | 72 | $206.81 | $15K | 18,386 | Jul 27, 2026 |
| Jul 22, 2026 | Plewman Patrick | SVP for Diagnostic Services | small acquisition | 46 | $206.81 | $10K | 15,293 | Jul 27, 2026 |
| Jul 22, 2026 | Main Timothy L | Director | small acquisition | 21 | $206.81 | $4K | 22,460 | Jul 27, 2026 |
| Jul 22, 2026 | Samad Sam | Executive Vice President & CFO | award | 102 | $206.81 | $21K | 33,478 | Jul 27, 2026 |
| Jul 22, 2026 | Lassiter Wright III | Director | small acquisition | 6 | $206.81 | $1K | 10,323 | Jul 27, 2026 |
| Jul 22, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | small acquisition | 34 | $206.81 | $7K | 11,935 | Jul 27, 2026 |
| Jun 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | option exercise | 3,320 | $127.72 | $424K | 16,830 | Jun 8, 2026 |
| Jun 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | option exercise | 4,827 | $121.81 | $588K | 21,657 | Jun 8, 2026 |
| Jun 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | open-market sale10b5-1 | 8,147 | $200.00 | $2M | 13,510 | Jun 8, 2026 |
| Jun 1, 2026 | Davis J. E. | CEO and President, Director | open-market sale10b5-1 | 10,000 | $194.14 | $2M | 132,423 | Jun 2, 2026 |
| May 20, 2026 | Carter Robert B | Director | award | 1,142 | $0.00 | — | 3,853 | May 21, 2026 |
| May 20, 2026 | Gregg Vicky B | Director | award | 1,142 | $0.00 | — | 18,314 | May 21, 2026 |
| May 20, 2026 | Diaz Luis | Director | award | 1,142 | $0.00 | — | 5,196 | May 21, 2026 |
| May 20, 2026 | Main Timothy L | Director | award | 1,142 | $0.00 | — | 27,439 | May 21, 2026 |
| May 20, 2026 | Wentworth Timothy C | Director | award | 1,142 | $0.00 | — | 1,358 | May 21, 2026 |
| May 20, 2026 | Doi Tracey | Director | award | 1,142 | $0.00 | — | 7,748 | May 21, 2026 |
| May 20, 2026 | Ring Timothy M | Director | award | 1,142 | $0.00 | — | 31,140 | May 21, 2026 |
| May 20, 2026 | Lassiter Wright III | Director | award | 1,142 | $0.00 | — | 10,317 | May 21, 2026 |
| May 20, 2026 | Morrison Denise M | Director | award | 1,142 | $0.00 | — | 11,929 | May 21, 2026 |
| May 20, 2026 | Pfeiffer Gary M | Director | award | 1,142 | $0.00 | — | 31,005 | May 21, 2026 |
| Apr 20, 2026 | Samad Sam | Executive Vice President & CFO | award | 108 | $194.70 | $21K | 33,376 | Apr 24, 2026 |
| Apr 20, 2026 | Plewman Patrick | SVP for Diagnostic Services | small acquisition | 49 | $194.70 | $10K | 15,247 | Apr 24, 2026 |
| Apr 20, 2026 | Gregg Vicky B | Director | award | 68 | $194.70 | $13K | 17,172 | Apr 24, 2026 |
| Apr 20, 2026 | Carter Robert B | Director | small acquisition | 7 | $194.70 | $1K | 2,711 | Apr 24, 2026 |
| Apr 20, 2026 | Lassiter Wright III | Director | small acquisition | 6 | $194.70 | $1K | 9,063 | Apr 24, 2026 |
| Apr 20, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | small acquisition | 39 | $194.70 | $8K | 13,490 | Apr 24, 2026 |
| Apr 20, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | small acquisition | 37 | $194.70 | $7K | 11,901 | Apr 24, 2026 |
| Mar 9, 2026 | Wentworth Timothy C | Director | award | 215 | $0.00 | — | 215 | Mar 11, 2026 |
| Mar 5, 2026 | Doherty Catherine T. | EVP, Regional Businesses | open-market sale10b5-1 | 5,558 | $206.21 | $1M | 67,122 | Mar 6, 2026 |
| Mar 5, 2026 | Prevoznik Michael E | SVP & General Counsel | open-market sale10b5-1 | 3,878 | $206.21 | $800K | 37,557 | Mar 6, 2026 |
| Mar 5, 2026 | Plewman Patrick | SVP for Diagnostic Services | open-market sale10b5-1 | 2,855 | $206.21 | $589K | 15,198 | Mar 6, 2026 |
| Mar 4, 2026 | Samad Sam | Executive Vice President & CFO | award | 13,947 | $204.86 | $3M | 40,988 | Mar 6, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Davis J. E. | CEO and President, Director | Sep 1, 2026 | open-market sale | 122,423 | — | $17M (6) | 6 of 6 |
| Doherty Catherine T. | EVP, Regional Businesses | Mar 5, 2026 | open-market sale | 67,122 | — | $7M (8) | 8 of 8 |
| Prevoznik Michael E | SVP & General Counsel | Aug 28, 2026 | option exercise | 60,234 | — | $7M (6) | 6 of 6 |
| Kuppusamy Karthik | SVP, Clinical Solutions | Oct 21, 2026 | small acquisition | 13,619 | — | $2M (2) | 1 of 2 |
| Plewman Patrick | SVP for Diagnostic Services | Oct 21, 2026 | small acquisition | 15,334 | — | $2M (4) | 4 of 4 |
| Delaney Mark E | SVP & Chief Commercial Officer | Oct 21, 2026 | small acquisition | 10,360 | — | $2M (2) | 2 of 2 |
| Pfeiffer Gary M | Director | Oct 26, 2026 | open-market sale | 29,802 | — | $292K (1) | 1 of 1 |
| Gregg Vicky B | Director | Oct 21, 2026 | award | 18,449 | — | $240K (1) | 0 of 1 |
| Samad Sam | Executive Vice President & CFO | Oct 21, 2026 | award | 33,568 | — | — | — |
| Deppe Michael J | SVP, Corp. Controller & CAO | Mar 4, 2026 | award | 35,946 | — | — | — |
| Carter Robert B | Director | Oct 21, 2026 | small acquisition | 3,874 | — | — | — |
| Lassiter Wright III | Director | Oct 21, 2026 | small acquisition | 10,329 | — | — | — |
| Main Timothy L | Director | Oct 21, 2026 | small acquisition | 22,478 | — | — | — |
| Diaz Luis | Director | May 20, 2026 | award | 5,196 | — | — | — |
| Wentworth Timothy C | Director | May 20, 2026 | award | 1,358 | — | — | — |
| Doi Tracey | Director | May 20, 2026 | award | 7,748 | — | — | — |
| Ring Timothy M | Director | May 20, 2026 | award | 31,140 | — | — | — |
| Morrison Denise M | Director | May 20, 2026 | award | 11,929 | — | — | — |
Questions
Are Quest Diagnostics Inc. insiders buying or selling?
Over the twelve months to November 1, 2026, 8 insiders at Quest Diagnostics Inc. sold $37M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $37M. Only open-market purchases and sales are counted.
Who sold the most Quest Diagnostics Inc. stock in the last year?
Davis J. E. (CEO and President, Director) sold $17M in 6 open-market sales over the twelve months to November 1, 2026.
Do Quest Diagnostics Inc. executives sell under 10b5-1 plans?
28 of the 30 open-market sales in the last twelve months (93%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Quest Diagnostics Inc.
- Quest Diagnostics Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.